Characteristics of biological therapy in pediatric patients with Crohn’s disease

References

• Benchimol EI, Fortinsky KJ, Gozdyra P, et al. Epidemiology of pediatric inflammatory bowel disease: a systematic review of international trends. Inflamm Bowel Dis. 2011;17(1):423–439.
   PubMed Web of Science ®Google Scholar
• Ruel J, Ruane D, Mehandru S, et al. IBD across the age spectrum: is it the same disease? Nat Rev Gastroenterol Hepatol. 2014;11(2):88–98.
   PubMed Web of Science ®Google Scholar
• Ruemmele FM, Veres G, Kolho KL, et al. Consensus guidelines of ECCO/ESPGHAN on the medical management of pediatric Crohn’s disease. J Crohns Colitis. 2014;8(10):1179–1207.
   PubMed Web of Science ®Google Scholar
• Lobo ED, Hansen RJ, Balthasar JP. Antibody pharmacokinetics and pharmacodynamics. J Pharm Sci. 2004;93(11):2645–2668.
   PubMed Web of Science ®Google Scholar
• Wyant T, Fedyk E, Abhyankar B. An overview of the mechanism of action of the monoclonal antibody vedolizumab. J Crohns Colitis. 2016;10(12):1437–1444.
   PubMed Web of Science ®Google Scholar
• Benson JM, Peritt D, Scallon BJ, et al. Discovery and mechanism of ustekinumab: a human monoclonal antibody targeting interleukin-12 and interleukin-23 for treatment of immune-mediated disorders. MAbs. 2011;3(6):535–545.
   PubMed Web of Science ®Google Scholar
• Vande Casteele N, Gils A. Pharmacokinetics of anti-TNF monoclonal antibodies in inflammatory bowel disease: adding value to current practice. J Clin Pharmacol. 2015;55(Suppl 3):S39–S50.
   PubMed Web of Science ®Google Scholar
• Kaymakcalan Z, Sakorafas P, Bose S, et al. Comparisons of affinities, avidities, and complement activation of adalimumab, infliximab, and etanercept in binding to soluble and membrane tumor necrosis factor. Clin Immunol. 2009;131(2):308–316.
   PubMed Web of Science ®Google Scholar
• Levin AD, Koelink PJ, Bloemendaal FM, et al. Autophagy contributes to the induction of anti-TNF induced macrophages. J Crohn’s Colitis. 2016;10(3):323–329.
   Google Scholar
• Zundler S, Neurath MF. Novel insights into the mechanisms of gut homing and antiadhesion therapies in inflammatory bowel diseases. Inflamm Bowel Dis. 2017;23(4):617–627.
   PubMed Web of Science ®Google Scholar
• Simon EG, Samuel S, Ghosh S, et al. Ustekinumab: a novel therapeutic option in Crohn’s disease. Expert Opin Biol Ther. 2016;16(8):1065–1074.
   PubMed Web of Science ®Google Scholar
• Feagan BG, Sandborn WJ, Gasink C, et al. Ustekinumab as induction and maintenance therapy for Crohn’s disease. N Engl J Med. 2016;375(20):1946–1960.
   PubMed Web of Science ®Google Scholar
• Jaramillo CAC, Belli S, Cascais A-C, et al. Toward in vitro-to-in vivo translation of monoclonal antibody pharmacokinetics: application of a neonatal Fc receptor-mediated transcytosis assay to understand the interplaying clearance mechanisms. MAbs. 2017;9(5):781–791.
   PubMed Web of Science ®Google Scholar
• Hemperly A, Vande Casteele N. Clinical pharmacokinetics and pharmacodynamics of infliximab in the treatment of inflammatory bowel disease. Clin Pharmacokinet. 2018.
   PubMedGoogle Scholar
• Rosario M, Dirks NL, Milch C, et al. A review of the clinical pharmacokinetics, pharmacodynamics, and immunogenicity of vedolizumab. Clin Pharmacokinet. 2017;56(11):1287–1301.
   PubMed Web of Science ®Google Scholar
• Dotan I, Ron Y, Yanai H, et al. Patient factors that increase infliximab clearance and shorten half-life in inflammatory bowel disease: a population pharmacokinetic study. Inflamm Bowel Dis. 2014;20(12):2247–2259.
   PubMed Web of Science ®Google Scholar
• Sharma S, Eckert D, Hyams JS, et al. Pharmacokinetics and exposure-efficacy relationship of adalimumab in pediatric patients with moderate to severe Crohn’s disease: results from a randomized, multicenter, phase-3 study. Inflamm Bowel Dis. 2015;21(4):783–792.
   PubMed Web of Science ®Google Scholar
• Zhu Y, Hu C, Lu M, et al. Population pharmacokinetic modeling of ustekinumab, a human monoclonal antibody targeting IL-12/23p40, in patients with moderate to severe plaque psoriasis. J Clin Pharmacol. 2009;49(2):162–175.
   PubMed Web of Science ®Google Scholar
• Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial. Lancet. 2002;359(9317):1541–1549.
   PubMed Web of Science ®Google Scholar
• Rutgeerts P, Feagan BG, Lichtenstein GR, et al. Comparison of scheduled and episodic treatment strategies of infliximab in Crohn’s disease. Gastroenterology. 2004;126(2):402–413.
   PubMed Web of Science ®Google Scholar
• Hyams J, Crandall W, Kugathasan S, et al. Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn’s disease in children. Gastroenterology. 2007;132(3):863–873.
   PubMed Web of Science ®Google Scholar
• Hanauer SB, Sandborn WJ, Rutgeerts P, et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn’s disease: the CLASSIC-I trial. Gastroenterology. 2006;130(2):323–333.
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Hanauer SB, Rutgeerts P, et al. Adalimumab for maintenance treatment of Crohn’s disease: results of the CLASSIC II trial. Gut. 2007;56(9):1232–1239.
   PubMed Web of Science ®Google Scholar
• Hyams JS, Griffiths A, Markowitz J, et al. Safety and efficacy of adalimumab for moderate to severe Crohn’s disease in children. Gastroenterology. 2012;143(2): 365–374 e2.
   PubMed Web of Science ®Google Scholar
• Cozijnsen M, Duif V, Kindermann A, et al. Adalimumab therapy in children with Crohn disease previously treated with infliximab. J Pediatr Gastroenterol Nutr. 2015;60(2):205–210.
   PubMed Web of Science ®Google Scholar
• Kierkus J, Dadalski M, Szymanska E, et al. The impact of infliximab induction therapy on mucosal healing and clinical remission in Polish pediatric patients with moderate-to-severe Crohn’s disease. Eur J Gastroenterol Hepatol. 2012;24(5):495–500.
   PubMed Web of Science ®Google Scholar
• Carla-Moreau A, Paul S, Roblin X, et al. Prevention and treatment of postoperative Crohn’s disease recurrence with anti-TNF therapy: a meta-analysis of controlled trials. Dig Liver Dis. 2015;47(3):191–196.
   PubMedGoogle Scholar
• Nuti F, Civitelli F, Bloise S, et al. Prospective evaluation of the achievement of mucosal healing with anti-TNF-alpha therapy in a paediatric Crohn’s disease cohort. J Crohns Colitis. 2016;10(1):5–12.
   PubMed Web of Science ®Google Scholar
• Nobile S, Gionchetti P, Rizzello F, et al. Mucosal healing in pediatric Crohn’s disease after anti-TNF therapy: a long-term experience at a single center. Eur J Gastroenterol Hepatol. 2014;26(4):458–465.
   PubMed Web of Science ®Google Scholar
• Walters TD, Kim M-O, Denson LA, et al. Increased effectiveness of early therapy with anti-tumor necrosis factor-alpha vs an immunomodulator in children with Crohn’s disease. Gastroenterology. 2014;146(2):383–391.
   PubMed Web of Science ®Google Scholar
• Kang B, Choi SY, Kim HS, et al. Mucosal healing in paediatric patients with moderate-to-severe luminal Crohn’s disease under combined immunosuppression: escalation versus early treatment. J Crohn’s Colitis. 2016;10(11):1279–1286.
   Google Scholar
• Kugathasan S, Denson LA, Walters TD, et al. Prediction of complicated disease course for children newly diagnosed with Crohn’s disease: a multicentre inception cohort study. Lancet. 2017;389(10080):1710–1718.
   PubMed Web of Science ®Google Scholar
• Assa A, Hartman C, Weiss B, et al. Long-term outcome of tumor necrosis factor alpha antagonist’s treatment in pediatric Crohn’s disease. J Crohns Colitis. 2013;7(5):369–376.
   PubMed Web of Science ®Google Scholar
• Nuti F, Viola F, Civitelli F, et al. Biological therapy in a pediatric Crohn disease population at a referral center. J Pediatr Gastroenterol Nutr. 2014;58(5):582–587.
   PubMed Web of Science ®Google Scholar
• De Bie CI, Hummel TZ, Kindermann A, et al. The duration of effect of infliximab maintenance treatment in paediatric Crohn’s disease is limited. Aliment Pharmacol Ther. 2011;33(2):243–250.
   PubMed Web of Science ®Google Scholar
• Grossi V, Lerer T, Griffiths A, et al. Concomitant use of immunomodulators affects the durability of infliximab therapy in children with Crohn’s disease. Clin Gastroenterol Hepatol. 2015;13(10):1748–1756.
   PubMed Web of Science ®Google Scholar
• deBruyn JC, Jacobson K, El-Matary W, et al. Long-term outcomes of infliximab use for pediatric Crohn disease: a Canadian multicenter clinical practice experience. J Pediatr Gastroenterol Nutr. 2018;66(2):268–273.
   PubMed Web of Science ®Google Scholar
• Faubion WA, Dubinsky M, Ruemmele FM, et al. Long-term efficacy and safety of adalimumab in pediatric patients with Crohn’s disease. Inflamm Bowel Dis. 2017;23(3):453–460.
   PubMed Web of Science ®Google Scholar
• Singh S, Andersen NN, Andersson M, et al. Comparison of infliximab with adalimumab in 827 biologic-naive patients with Crohn’s disease: a population-based Danish cohort study. Aliment Pharmacol Ther. 2018;47(5):596–604.
   PubMed Web of Science ®Google Scholar
• Olivera P, Thiriet L, Luc A, et al. Treatment persistence for infliximab versus adalimumab in Crohn’s disease: a 14-year single-center experience. Inflamm Bowel Dis. 2017;23(6):976–985.
   PubMed Web of Science ®Google Scholar
• Colombel JF, Sandborn WJ, Reinisch W, et al. Infliximab, azathioprine, or combination therapy for Crohn’s disease. N Engl J Med. 2010;362(15):1383–1395.
   PubMed Web of Science ®Google Scholar
• Feagan BG, McDonald JWD, Panaccione R, et al. Methotrexate in combination with infliximab is no more effective than infliximab alone in patients with Crohn’s disease. Gastroenterology. 2014;146(3): 681–688 e1.
   PubMed Web of Science ®Google Scholar
• Church PC, Guan J, Walters TD, et al. Infliximab maintains durable response and facilitates catch-up growth in luminal pediatric Crohn’s disease. Inflamm Bowel Dis. 2014;20(7):1177–1186.
   PubMed Web of Science ®Google Scholar
• Ungar B, Kopylov U, Engel T, et al. Addition of an immunomodulator can reverse antibody formation and loss of response in patients treated with adalimumab. Aliment Pharmacol Ther. 2017;45(2):276–282.
   PubMed Web of Science ®Google Scholar
• Strik AS, van Den Brink GR, Ponsioen C, et al. Suppression of anti-drug antibodies to infliximab or adalimumab with the addition of an immunomodulator in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2017;45(8):1128–1134.
   PubMed Web of Science ®Google Scholar
• Ding NS, Hart A, De Cruz P. Systematic review: predicting and optimising response to anti-TNF therapy in Crohn’s disease - algorithm for practical management. Aliment Pharmacol Ther. 2016;43(1):30–51.
   PubMed Web of Science ®Google Scholar
• Ben-Horin S, Chowers Y. Review article: loss of response to anti-TNF treatments in Crohn’s disease. Aliment Pharmacol Ther. 2011;33(9):987–995.
   PubMed Web of Science ®Google Scholar
• Vande Casteele N, Ferrante M, Van Assche G, et al. Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease. Gastroenterology. 2015;148(7): 1320–1329 e3.
   PubMed Web of Science ®Google Scholar
• Kansen HM, van Rheenen PF, Houwen RHJ, et al. Less anti-infliximab antibody formation in paediatric Crohn patients on concomitant immunomodulators. J Pediatr Gastroenterol Nutr. 2017;65(4):425–429.
   PubMed Web of Science ®Google Scholar
• Dupont-Lucas C, Sternszus R, Ezri J, et al. Identifying patients at high risk of loss of response to infliximab maintenance therapy in paediatric Crohn’s disease. J Crohns Colitis. 2016;10(7):795–804.
   PubMed Web of Science ®Google Scholar
• van Hoeve K, Dreesen E, Hoffman I, et al. Higher infliximab trough levels are associated with better outcome in paediatric patients with inflammatory bowel disease. J Crohns Colitis. 2018;12(11):1316–1325.
   PubMed Web of Science ®Google Scholar
• Louis E, Mary J-Y, Vernier-Massouille G, et al. Maintenance of remission among patients with Crohn’s disease on antimetabolite therapy after infliximab therapy is stopped. Gastroenterology. 2012;142(1):63–70 e5; quiz e31.
   PubMed Web of Science ®Google Scholar
• Van Assche G, Magdelaine-Beuzelin C, D’Haens G, et al. Withdrawal of immunosuppression in Crohn’s disease treated with scheduled infliximab maintenance: a randomized trial. Gastroenterology. 2008;134(7):1861–1868.
   PubMed Web of Science ®Google Scholar
• Cseh Á, Nemes É, Tárnok A, et al. Long-term follow-up in children with Crohn’s disease with infliximab therapy: the PIT-STOP multicenter study. J Pediatr Gastroenterol Nutr. 2017;64(Supplement 1):464.
   Google Scholar
• Molnár T, Lakatos PL, Farkas K, et al. Predictors of relapse in patients with Crohn’s disease in remission after 1 year of biological therapy. Aliment Pharmacol Ther. 2013;37(2):225–233.
   PubMed Web of Science ®Google Scholar
• Pigneur B, Seksik P, Viola S, et al. Natural history of Crohn’s disease: comparison between childhood- and adult-onset disease. Inflamm Bowel Dis. 2010;16(6):953–961.
   PubMed Web of Science ®Google Scholar
• Eberhardson M, Söderling JK, Neovius M, et al. Anti-TNF treatment in Crohn’s disease and risk of bowel resection-a population based cohort study. Aliment Pharmacol Ther. 2017;46(6):589–598.
   PubMed Web of Science ®Google Scholar
• Assa A, Bronsky J, Kolho K-L, et al. Anti-TNFalpha treatment after surgical resection for Crohn’s disease is effective despite previous pharmacodynamic failure. Inflamm Bowel Dis. 2017;23(5):791–797.
   PubMed Web of Science ®Google Scholar
• Singh S, Garg SK, Pardi DS, et al. Comparative efficacy of pharmacologic interventions in preventing relapse of Crohn’s disease after surgery: a systematic review and network meta-analysis. Gastroenterology. 2015;148(1): 64–76.e2; quiz e14.
   PubMed Web of Science ®Google Scholar
• Splawski JB, Pffefferkorn MD, Schaefer ME, et al. NASPGHAN clinical report on postoperative recurrence in pediatric Crohn disease. J Pediatr Gastroenterol Nutr. 2017;65(4):475–486.
   PubMed Web of Science ®Google Scholar
• Diederen K, de Ridder L, van Rheenen P, et al. Complications and disease recurrence after primary ileocecal resection in pediatric Crohn’s disease: a multicenter cohort analysis. Inflamm Bowel Dis. 2017;23(2):272–282.
   PubMed Web of Science ®Google Scholar
• Sands BE, Anderson FH, Bernstein CN, et al. Infliximab maintenance therapy for fistulizing Crohn’s disease. N Engl J Med. 2004;350(9):876–885.
   PubMed Web of Science ®Google Scholar
• Colombel JF, Sandborn WJ, Rutgeerts P, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn’s disease: the CHARM trial. Gastroenterology. 2007;132(1):52–65.
   PubMed Web of Science ®Google Scholar
• Crandall W, Hyams J, Kugathasan S, et al. Infliximab therapy in children with concurrent perianal Crohn disease: observations from REACH. J Pediatr Gastroenterol Nutr. 2009;49(2):183–190.
   PubMed Web of Science ®Google Scholar
• Dupont-Lucas C, Dabadie A, Alberti C, et al. Predictors of response to infliximab in paediatric perianal Crohn’s disease. Aliment Pharmacol Ther. 2014;40(8):917–929.
   PubMed Web of Science ®Google Scholar
• Assa A, Amitai M, Greer ML, et al. Perianal pediatric Crohn disease is associated with a distinct phenotype and greater inflammatory burden. J Pediatr Gastroenterol Nutr. 2017;65(3):293–298.
   PubMed Web of Science ®Google Scholar
• Amil-Dias J, Kolacek S, Turner D, et al. Surgical management of Crohn disease in children: guidelines from the paediatric IBD Porto Group of ESPGHAN. J Pediatr Gastroenterol Nutr. 2017;64(5):818–835.
   PubMed Web of Science ®Google Scholar
• Ji CC, Takano S. Clinical efficacy of adalimumab versus infliximab and the factors associated with recurrence or aggravation during treatment of anal fistulas in Crohn’s disease. Intest Res. 2017;15(2):182–186.
   PubMed Web of Science ®Google Scholar
• D’Haens G. Risks and benefits of biologic therapy for inflammatory bowel diseases. Gut. 2007;56(5):725–732.
   PubMed Web of Science ®Google Scholar
• Freling E, Baumann C, Cuny J-F, et al. Cumulative incidence of, risk factors for, and outcome of dermatological complications of anti-TNF therapy in inflammatory bowel disease: a 14-year experience. Am J Gastroenterol. 2015;110(8):1186–1196.
   PubMed Web of Science ®Google Scholar
• Andrade P, Lopes S, Gaspar R, et al. Anti-tumor necrosis factor-alpha-induced dermatological complications in a large cohort of inflammatory bowel disease patients. Dig Dis Sci. 2018;63(3):746–754.
   PubMed Web of Science ®Google Scholar
• Malkonen T, Wikström A, Heiskanen K, et al. Skin reactions during anti-TNFalpha therapy for pediatric inflammatory bowel disease: a 2-year prospective study. Inflamm Bowel Dis. 2014;20(8):1309–1315.
   PubMed Web of Science ®Google Scholar
• Singh N, Rabizadeh S, Jossen J, et al. Multi-center experience of vedolizumab effectiveness in pediatric inflammatory bowel disease. Inflamm Bowel Dis. 2016;22(9):2121–2126.
   PubMed Web of Science ®Google Scholar
• Gupta G, Gelfand JM, Lewis JD. Increased risk for demyelinating diseases in patients with inflammatory bowel disease. Gastroenterology. 2005;129(3):819–826.
   PubMed Web of Science ®Google Scholar
• Tristano AG. Neurological adverse events associated with anti-tumor necrosis factor alpha treatment. J Neurol. 2010;257(9):1421–1431.
   PubMed Web of Science ®Google Scholar
• Ramos-Casals M, Diaz-Lagares C, Cuadrado MJ, et al. Autoimmune diseases induced by biological agents: a double-edged sword? Autoimmun Rev. 2010;9(3):188–193.
   PubMed Web of Science ®Google Scholar
• Ford AC, Peyrin-Biroulet L. Opportunistic infections with anti-tumor necrosis factor-alpha therapy in inflammatory bowel disease: meta-analysis of randomized controlled trials. Am J Gastroenterol. 2013;108(8):1268–1276.
   PubMed Web of Science ®Google Scholar
• Peyrin-Biroulet L, Deltenre P, de Suray N, et al. Efficacy and safety of tumor necrosis factor antagonists in Crohn’s disease: meta-analysis of placebo-controlled trials. Clin Gastroenterol Hepatol. 2008;6(6):644–653.
   PubMed Web of Science ®Google Scholar
• Stoll ML, Grubbs JA, Beukelman T, et al. Risk of tuberculosis among Alabama children and adolescents treated with tumor necrosis factor inhibitors: a retrospective study. Pediatr Rheumatol Online J. 2017;15(1):79.
   PubMedGoogle Scholar
• de Ridder L, Turner D, Wilson DC, et al. Malignancy and mortality in pediatric patients with inflammatory bowel disease: a multinational study from the porto pediatric IBD group. Inflamm Bowel Dis. 2014;20(2):291–300.
   PubMed Web of Science ®Google Scholar
• Joosse ME, Aardoom MA, Kemos P, et al. Malignancy and mortality in paediatric-onset inflammatory bowel disease: a 3-year prospective, multinational study from the paediatric IBD Porto Group of ESPGHAN. Aliment Pharmacol Ther. 2018;48(5):523–537.
   PubMed Web of Science ®Google Scholar
• Hanauer S, Rutgeerts P, Targan S, et al. Delayed hypersensitivity to infliximab [Remicade] re-infusion after a 2–4 year interval without treatment. Gastroenterology. 1999;116(A731) (abstract).
   Google Scholar
• Katsanos KH, Voulgari PV, Tsianos EV. Inflammatory bowel disease and lupus: a systematic review of the literature. J Crohns Colitis. 2012;6(7):735–742.
   PubMed Web of Science ®Google Scholar
• Tsuchiya M, Okazaki I, Asakura H, et al. Radiographic and endoscopic features of colonic ulcers in systemic lupus erythematosus. Am J Gastroenterol. 1975;64(4):277–285.
   PubMed Web of Science ®Google Scholar
• Vermeire S, Rutgeerts P. Antibody responses in Crohnx’s disease. Gastroenterology. 2004;126(2):601–604.
   PubMed Web of Science ®Google Scholar
• Kappelman MD, Galanko JA, Porter CQ, et al. Association of paediatric inflammatory bowel disease with other immune-mediated diseases. Arch Dis Child. 2011;96(11):1042–1046.
   PubMed Web of Science ®Google Scholar
• Lopez-Olivo MA, Tayar JH, Martinez-Lopez JA, et al. Risk of malignancies in patients with rheumatoid arthritis treated with biologic therapy: a meta-analysis. Jama. 2012;308(9):898–908.
   PubMed Web of Science ®Google Scholar
• Williams CJ, Peyrin-Biroulet L, Ford AC. Systematic review with meta-analysis: malignancies with anti-tumour necrosis factor-alpha therapy in inflammatory bowel disease. Aliment Pharmacol Ther. 2014;39(5):447–458.
   PubMed Web of Science ®Google Scholar
• Herrinton LJ, Liu L, Weng X, et al. Role of thiopurine and anti-TNF therapy in lymphoma in inflammatory bowel disease. Am J Gastroenterol. 2011;106(12):2146–2153.
   PubMed Web of Science ®Google Scholar
• Osterman MT, Sandborn WJ, Colombel J-F, et al. Increased risk of malignancy with adalimumab combination therapy, compared with monotherapy, for Crohn’s disease. Gastroenterology. 2014;146(4):941–949.
   PubMed Web of Science ®Google Scholar
• Olen O, Askling J, Sachs MC, et al. Childhood onset inflammatory bowel disease and risk of cancer: a Swedish nationwide cohort study 1964–2014. BMJ. 2017;358:j3951.
   PubMed Web of Science ®Google Scholar
• Summary Basis of Decision (SBD): Remsima. Health Canada; 2015. [cited 2018 Aug 5th]. Available from: http://www.hc-sc.gc.ca/dhp-mps/prodpharma/sbd-smd/drug-ed/sbd_smd_2014_remsima_160195-eng.php
   Google Scholar
• Buer L, Høivik ML, Medhus AW, et al. Does the introduction of biosimilars change our understanding about treatment modalities for inflammatory bowel disease? Dig Dis. 2017;35(1–2):74–82.
   PubMed Web of Science ®Google Scholar
• Feagan BG, Choquette D, Ghosh S, et al. The challenge of indication extrapolation for infliximab biosimilars. Biologicals. 2014;42(4):177–183.
   PubMed Web of Science ®Google Scholar
• Gomollon F. Biosimilars: are they bioequivalent? Dig Dis. 2014;32(Suppl 1):82–87.
   PubMed Web of Science ®Google Scholar
• Zheng MK, Shih DQ, Chen GC. Insights on the use of biosimilars in the treatment of inflammatory bowel disease. World J Gastroenterol. 2017;23(11):1932–1943.
   PubMed Web of Science ®Google Scholar
• Canadian Agency for Drugs and Technologies in Health. Switching from innovator to biosimilar (subsequent entry) infliximab: an updated review of the clinical effectiveness, cost-effectiveness, and guidelines. Ottawa (ON); 2017. pp. 1-30.
   Google Scholar
• Farkas K, Rutka M, Bálint A, et al. Efficacy of the new infliximab biosimilar CT-P13 induction therapy in Crohn’s disease and ulcerative colitis - experiences from a single center. Expert Opin Biol Ther. 2015;15(9):1257–1262.
   PubMed Web of Science ®Google Scholar
• Gecse KB, Lovász BD, Farkas K, et al. Efficacy and safety of the biosimilar infliximab CT-P13 treatment in inflammatory bowel diseases: a prospective, multicentre, nationwide cohort. J Crohns Colitis. 2016;10(2):133–140.
   PubMed Web of Science ®Google Scholar
• Ha CY, Kornbluth A. A critical review of biosimilars in IBD: the confluence of biologic drug development, regulatory requirements, clinical outcomes, and big business. Inflamm Bowel Dis. 2016;22(10):2513–2526.
   PubMed Web of Science ®Google Scholar
• Jahnsen J, Detlie TE, Vatn S, et al. Biosimilar infliximab (CT-P13) in the treatment of inflammatory bowel disease: a Norwegian observational study. Expert Rev Gastroenterol Hepatol. 2015;9(Suppl 1):45–52.
   PubMedGoogle Scholar
• Jung YS, Park DI, Kim YH, et al. Efficacy and safety of CT-P13, a biosimilar of infliximab, in patients with inflammatory bowel disease: A retrospective multicenter study. J Gastroenterol Hepatol. 2015;30(12):1705–1712.
   PubMed Web of Science ®Google Scholar
• Keil R, Wasserbauer M, Zádorová Z, et al. Clinical monitoring: infliximab biosimilar CT-P13 in the treatment of Crohn’s disease and ulcerative colitis. Scand J Gastroenterol. 2016;51(9):1062–1068.
   PubMed Web of Science ®Google Scholar
• Park DI. Current status of biosimilars in the treatment of inflammatory bowel diseases. Intest Res. 2016;14(1):15–20.
   PubMed Web of Science ®Google Scholar
• Sieczkowska J, Jarzębicka D, Banaszkiewicz A, et al. Switching between infliximab originator and biosimilar in paediatric patients with inflammatory bowel disease. Preliminary observations. J Crohns Colitis. 2016;10(2):127–132.
   PubMed Web of Science ®Google Scholar
• Sieczkowska J, Jarzębicka D, Meglicka M, et al. Experience with biosimilar infliximab (CT-P13) in paediatric patients with inflammatory bowel diseases. Therap Adv Gastroenterol. 2016;9(5):729–735.
   PubMed Web of Science ®Google Scholar
• Jorgensen KK, Olsen IC, Goll GL, et al. Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial. Lancet. 2017;389(10086):2304–2316.
   PubMed Web of Science ®Google Scholar
• Fasanmade, AA, Adedokun OJ, Blank M, et al. Pharmacokinetic properties of infliximab in children and adults with Crohn’s disease: a retrospective analysis of data from 2 phase III clinical trials. Clin Ther. 2011;33(7):946–964.
   PubMed Web of Science ®Google Scholar
• Jongsma MME, Vulto A, de Ridder L. The use of biosimilars in paediatric inflammatory bowel disease. Curr Opin Pediatr. 2017;29(5):560–565.
   PubMed Web of Science ®Google Scholar
• Jha A, Upton A, Dunlop WCN, et al. The budget impact of biosimilar infliximab (Remsima(R)) for the treatment of autoimmune diseases in five European countries. Adv Ther. 2015;32(8):742–756.
   PubMed Web of Science ®Google Scholar
• Kanters TA, Stevanovic J, Huys I, et al. Adoption of biosimilar infliximab for rheumatoid arthritis, ankylosing spondylitis, and inflammatory bowel diseases in the EU5: a budget impact analysis using a Delphi panel. Front Pharmacol. 2017;8:322.
   PubMed Web of Science ®Google Scholar
• Feagan BG, Rutgeerts P, Sands BE, et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2013;369(8):699–710.
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Feagan BG, Rutgeerts P, et al. Vedolizumab as induction and maintenance therapy for Crohn’s disease. N Engl J Med. 2013;369(8):711–721.
   PubMed Web of Science ®Google Scholar
• Schreiber S, Dignass A, Peyrin-Biroulet L, et al. Systematic review with meta-analysis: real-world effectiveness and safety of vedolizumab in patients with inflammatory bowel disease. J Gastroenterol. 2018;53(9):1048–1064.
   PubMed Web of Science ®Google Scholar
• Kopylov U, Verstockt B, Biedermann L, et al. Effectiveness and safety of vedolizumab in anti-TNF-naïve patients with inflammatory bowel disease—a multicenter retrospective European study. Inflamm Bowel Dis. 2018;24(11):2442–2551.
   Web of Science ®Google Scholar
• Conrad MA, Stein RE, Maxwell EC, et al. Vedolizumab therapy in severe pediatric inflammatory bowel disease. Inflamm Bowel Dis. 2016;22(10):2425–2431.
   PubMed Web of Science ®Google Scholar
• Ledder O, Assa A, Levine A, et al. Vedolizumab in paediatric inflammatory bowel disease: a retrospective multi-centre experience from the paediatric IBD Porto Group of ESPGHAN. J Crohn’s Colitis. 2017;11(10):1230–1237.
   Google Scholar
• Zimmerman LA, Zalieckas JM, Shamberger RC, et al. Postoperative complications of pediatric patients with inflammatory bowel disease treated with vedolizumab. J Pediatr Surg. 2018;53(7):1330–1333.
   PubMed Web of Science ®Google Scholar
• Lightner AL, Tse CS, Potter DD, et al. Postoperative outcomes in vedolizumab-treated pediatric patients undergoing abdominal operations for inflammatory bowel disease. J Pediatr Surg. 2018;53(9):1706–1709.
   PubMed Web of Science ®Google Scholar
• Ma C, Fedorak RN, Kaplan GG, et al. Clinical, endoscopic and radiographic outcomes with ustekinumab in medically-refractory Crohn’s disease: real world experience from a multicentre cohort. Aliment Pharmacol Ther. 2017;45(9):1232–1243.
   PubMed Web of Science ®Google Scholar
• Rinawi F, Rosenbach Y, Assa A, et al. Ustekinumab for resistant pediatric Crohn disease. J Pediatr Gastroenterol Nutr. 2016;62(4):e34–e5.
   PubMed Web of Science ®Google Scholar
• Bishop C, et al. Ustekinumab in pediatric Crohn disease patients. J Pediatr Gastroenterol Nutr. 2016;63(3):348–351.
   PubMed Web of Science ®Google Scholar
• Selinger C, Sandborn W, Panes J, et al. OTU-003 Etrolizumab as induction therapy in moderate to severe Crohn’s disease: results from BERGAMOT cohort 1. Gut. 2018;67(Suppl 1):A53–A53.
   PubMedGoogle Scholar
• Feagan BG, Sandborn WJ, D’Haens G, et al. Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn’s disease: a randomised, double-blind, placebo-controlled phase 2 study. Lancet. 2017;389(10080):1699–1709.
   PubMed Web of Science ®Google Scholar
• Feagan BG, Panes J, Ferrante M, et al. Efficacy and safety of open-label maintenance therapy with subcutaneous risankizumab in patients with moderateto-severe Crohn’s disease. Gastroenterology. 2017;152(5):S1310.
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Feagan BG, Panes J, et al. Safety and efficacy of ABT-494 (upadacitinib), an oral JAK1 inhibitor, as induction therapy in patients with Crohn’s disease: results from CELEST. Gastroenterology. 2017;152(5):S1308–S1309.
   Web of Science ®Google Scholar
• Vermeire S, Schreiber S, Petryka R, et al. Clinical remission in patients with moderate-to-severe Crohn’s disease treated with filgotinib (the FITZROY study): results from a phase 2, double-blind, randomised, placebo-controlled trial. Lancet. 2017;389(10066):266–275.
   PubMed Web of Science ®Google Scholar
• Feagan B, Sandborn W. Endoscopic and clinical efficacy demonstrated with oral ozanimod in moderately to severely active Crohn’s disease. Program no. P1272. World congress of gastroenterology at ACG2017 meeting abstracts. United European Gastroenterol J. 2017;5(supplement 1). Available from: https://www.ueg.eu/education/document/endoscopic-and-clinical-efficacy-demonstrated-with-oral-ozanimod-in-moderately-to-severely-active-crohn-s-disease/151626
   Google Scholar
• Danese S, Vermeire S, Hellstern P, et al. Randomised trial and open-label extension study of an anti-interleukin-6 antibody in Crohn’s disease (ANDANTE I and II). Gut. 2017;68(1):40–48.
   Web of Science ®Google Scholar
• Chaparro M, Verreth A, Lobaton T, et al. Long-term safety of in utero exposure to anti-TNFalpha drugs for the treatment of inflammatory bowel disease: results from the multicenter European TEDDY study. Am J Gastroenterol. 2018;113(3):396–403.
   PubMed Web of Science ®Google Scholar
• Moens A, van Hoeve K, Humblet E, et al. Outcome of pregnancies in female patients with inflammatory bowel diseases treated with vedolizumab. J Crohns Colitis. 2018.
   Google Scholar
• Venturin C, Nancey S, Danion P, et al. Fetal death in utero and miscarriage in a patient with Crohn’s disease under therapy with ustekinumab: case-report and review of the literature. BMC Gastroenterol. 2017;17(1):80.
   PubMedGoogle Scholar
• Galluzzo M, D’Adamio S, Bianchi L, et al. Psoriasis in pregnancy: case series and literature review of data concerning exposure during pregnancy to ustekinumab. J Dermatological Treat. 2018;1–5.
   PubMed Web of Science ®Google Scholar